PMID- 28981385
OWN - NLM
STAT- MEDLINE
DCOM- 20190805
LR  - 20220410
IS  - 1527-7755 (Electronic)
IS  - 0732-183X (Print)
IS  - 0732-183X (Linking)
VI  - 36
IP  - 17
DP  - 2018 Jun 10
TI  - Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of 
      Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone 
      in Patients With Advanced, Unresectable Melanoma.
PG  - 1658-1667
LID - 10.1200/JCO.2017.73.7379 [doi]
AB  - Purpose We evaluated the combination of talimogene laherparepvec plus ipilimumab 
      versus ipilimumab alone in patients with advanced melanoma in a phase II study. 
      To our knowledge, this was the first randomized trial to evaluate addition of an 
      oncolytic virus to a checkpoint inhibitor. Methods Patients with unresectable 
      stages IIIB to IV melanoma, with no more than one prior therapy if BRAF 
      wild-type, no more than two prior therapies if BRAF mutant, measurable/injectable 
      disease, and without symptomatic autoimmunity or clinically significant 
      immunosuppression were randomly assigned 1:1 to receive talimogene laherparepvec 
      plus ipilimumab or ipilimumab alone. Talimogene laherparepvec treatment began in 
      week 1 (first dose, </= 4 mL x 10(6) plaque-forming units/mL; after 3 weeks, </= 4 mL 
      x 10(8) plaque-forming units/mL every 2 weeks). Ipilimumab (3 mg/kg every 3 
      weeks; up to four doses) began week 1 in the ipilimumab alone arm and week 6 in 
      the combination arm. The primary end point was objective response rate evaluated 
      by investigators per immune-related response criteria. Results One hundred 
      ninety-eight patients were randomly assigned to talimogene laherparepvec plus 
      ipilimumab (n = 98), or ipilimumab alone (n = 100). Thirty-eight patients (39%) 
      in the combination arm and 18 patients (18%) in the ipilimumab arm had an 
      objective response (odds ratio, 2.9; 95% CI, 1.5 to 5.5; P = .002). Responses 
      were not limited to injected lesions; visceral lesion decreases were observed in 
      52% of patients in the combination arm and 23% of patients in the ipilimumab arm. 
      Frequently occurring adverse events (AEs) included fatigue (combination, 59%; 
      ipilimumab alone, 42%), chills (combination, 53%; ipilimumab alone, 3%), and 
      diarrhea (combination, 42%; ipilimumab alone, 35%). Incidence of grade >/= 3 AEs 
      was 45% and 35%, respectively. Three patients in the combination arm had fatal 
      AEs; none were treatment related. Conclusion The study met its primary end point; 
      the objective response rate was significantly higher with talimogene 
      laherparepvec plus ipilimumab versus ipilimumab alone. These data indicate that 
      the combination has greater antitumor activity without additional safety concerns 
      versus ipilimumab.
FAU - Chesney, Jason
AU  - Chesney J
AD  - Jason Chesney, J. Graham Brown Cancer Center, University of Louisville, 
      Louisville, KY; Igor Puzanov, Roswell Park Cancer Institute, Buffalo; Philip 
      Friedlander, Mt Sinai School of Medicine, New York, NY; Frances Collichio, The 
      University of North Carolina at Chapel Hill, Chapel Hill, NC; Parminder Singh, 
      Mayo Clinic, Phoenix, AZ; Mohammed M. Milhem, University of Iowa Hospitals and 
      Clinics, Iowa City, IA; John Glaspy, University of California Los Angeles School 
      of Medicine; Omid Hamid, The Angeles Clinic and Research Institute, Los Angeles; 
      Lisa Chen, Jenny J. Kim, and Jennifer Gansert, Amgen, Thousand Oaks, CA; Merrick 
      Ross, MD Anderson Cancer Center, Houston, TX; Claus Garbe, University Hospital 
      Tuebingen, Tuebingen; Axel Hauschild, University of Kiel, Kiel, Germany; Theodore 
      F. Logan, Indiana University Simon Cancer Center, Indianapolis, IN; Celeste 
      Lebbe, Assistance Publique-Hopital De Paris Dermatology and CIC Hopital Saint 
      Louis University Paris Diderot Sorbonne, Institut National de la Sante et de la 
      Recherche Medicale U976, Paris, France; Robert H.I. Andtbacka, University of 
      Utah, Salt Lake City, UT; and Howard L. Kaufman, Rutgers Cancer Institute of New 
      Jersey, New Brunswick, NJ.
FAU - Puzanov, Igor
AU  - Puzanov I
AD  - Jason Chesney, J. Graham Brown Cancer Center, University of Louisville, 
      Louisville, KY; Igor Puzanov, Roswell Park Cancer Institute, Buffalo; Philip 
      Friedlander, Mt Sinai School of Medicine, New York, NY; Frances Collichio, The 
      University of North Carolina at Chapel Hill, Chapel Hill, NC; Parminder Singh, 
      Mayo Clinic, Phoenix, AZ; Mohammed M. Milhem, University of Iowa Hospitals and 
      Clinics, Iowa City, IA; John Glaspy, University of California Los Angeles School 
      of Medicine; Omid Hamid, The Angeles Clinic and Research Institute, Los Angeles; 
      Lisa Chen, Jenny J. Kim, and Jennifer Gansert, Amgen, Thousand Oaks, CA; Merrick 
      Ross, MD Anderson Cancer Center, Houston, TX; Claus Garbe, University Hospital 
      Tuebingen, Tuebingen; Axel Hauschild, University of Kiel, Kiel, Germany; Theodore 
      F. Logan, Indiana University Simon Cancer Center, Indianapolis, IN; Celeste 
      Lebbe, Assistance Publique-Hopital De Paris Dermatology and CIC Hopital Saint 
      Louis University Paris Diderot Sorbonne, Institut National de la Sante et de la 
      Recherche Medicale U976, Paris, France; Robert H.I. Andtbacka, University of 
      Utah, Salt Lake City, UT; and Howard L. Kaufman, Rutgers Cancer Institute of New 
      Jersey, New Brunswick, NJ.
FAU - Collichio, Frances
AU  - Collichio F
AD  - Jason Chesney, J. Graham Brown Cancer Center, University of Louisville, 
      Louisville, KY; Igor Puzanov, Roswell Park Cancer Institute, Buffalo; Philip 
      Friedlander, Mt Sinai School of Medicine, New York, NY; Frances Collichio, The 
      University of North Carolina at Chapel Hill, Chapel Hill, NC; Parminder Singh, 
      Mayo Clinic, Phoenix, AZ; Mohammed M. Milhem, University of Iowa Hospitals and 
      Clinics, Iowa City, IA; John Glaspy, University of California Los Angeles School 
      of Medicine; Omid Hamid, The Angeles Clinic and Research Institute, Los Angeles; 
      Lisa Chen, Jenny J. Kim, and Jennifer Gansert, Amgen, Thousand Oaks, CA; Merrick 
      Ross, MD Anderson Cancer Center, Houston, TX; Claus Garbe, University Hospital 
      Tuebingen, Tuebingen; Axel Hauschild, University of Kiel, Kiel, Germany; Theodore 
      F. Logan, Indiana University Simon Cancer Center, Indianapolis, IN; Celeste 
      Lebbe, Assistance Publique-Hopital De Paris Dermatology and CIC Hopital Saint 
      Louis University Paris Diderot Sorbonne, Institut National de la Sante et de la 
      Recherche Medicale U976, Paris, France; Robert H.I. Andtbacka, University of 
      Utah, Salt Lake City, UT; and Howard L. Kaufman, Rutgers Cancer Institute of New 
      Jersey, New Brunswick, NJ.
FAU - Singh, Parminder
AU  - Singh P
AD  - Jason Chesney, J. Graham Brown Cancer Center, University of Louisville, 
      Louisville, KY; Igor Puzanov, Roswell Park Cancer Institute, Buffalo; Philip 
      Friedlander, Mt Sinai School of Medicine, New York, NY; Frances Collichio, The 
      University of North Carolina at Chapel Hill, Chapel Hill, NC; Parminder Singh, 
      Mayo Clinic, Phoenix, AZ; Mohammed M. Milhem, University of Iowa Hospitals and 
      Clinics, Iowa City, IA; John Glaspy, University of California Los Angeles School 
      of Medicine; Omid Hamid, The Angeles Clinic and Research Institute, Los Angeles; 
      Lisa Chen, Jenny J. Kim, and Jennifer Gansert, Amgen, Thousand Oaks, CA; Merrick 
      Ross, MD Anderson Cancer Center, Houston, TX; Claus Garbe, University Hospital 
      Tuebingen, Tuebingen; Axel Hauschild, University of Kiel, Kiel, Germany; Theodore 
      F. Logan, Indiana University Simon Cancer Center, Indianapolis, IN; Celeste 
      Lebbe, Assistance Publique-Hopital De Paris Dermatology and CIC Hopital Saint 
      Louis University Paris Diderot Sorbonne, Institut National de la Sante et de la 
      Recherche Medicale U976, Paris, France; Robert H.I. Andtbacka, University of 
      Utah, Salt Lake City, UT; and Howard L. Kaufman, Rutgers Cancer Institute of New 
      Jersey, New Brunswick, NJ.
FAU - Milhem, Mohammed M
AU  - Milhem MM
AD  - Jason Chesney, J. Graham Brown Cancer Center, University of Louisville, 
      Louisville, KY; Igor Puzanov, Roswell Park Cancer Institute, Buffalo; Philip 
      Friedlander, Mt Sinai School of Medicine, New York, NY; Frances Collichio, The 
      University of North Carolina at Chapel Hill, Chapel Hill, NC; Parminder Singh, 
      Mayo Clinic, Phoenix, AZ; Mohammed M. Milhem, University of Iowa Hospitals and 
      Clinics, Iowa City, IA; John Glaspy, University of California Los Angeles School 
      of Medicine; Omid Hamid, The Angeles Clinic and Research Institute, Los Angeles; 
      Lisa Chen, Jenny J. Kim, and Jennifer Gansert, Amgen, Thousand Oaks, CA; Merrick 
      Ross, MD Anderson Cancer Center, Houston, TX; Claus Garbe, University Hospital 
      Tuebingen, Tuebingen; Axel Hauschild, University of Kiel, Kiel, Germany; Theodore 
      F. Logan, Indiana University Simon Cancer Center, Indianapolis, IN; Celeste 
      Lebbe, Assistance Publique-Hopital De Paris Dermatology and CIC Hopital Saint 
      Louis University Paris Diderot Sorbonne, Institut National de la Sante et de la 
      Recherche Medicale U976, Paris, France; Robert H.I. Andtbacka, University of 
      Utah, Salt Lake City, UT; and Howard L. Kaufman, Rutgers Cancer Institute of New 
      Jersey, New Brunswick, NJ.
FAU - Glaspy, John
AU  - Glaspy J
AD  - Jason Chesney, J. Graham Brown Cancer Center, University of Louisville, 
      Louisville, KY; Igor Puzanov, Roswell Park Cancer Institute, Buffalo; Philip 
      Friedlander, Mt Sinai School of Medicine, New York, NY; Frances Collichio, The 
      University of North Carolina at Chapel Hill, Chapel Hill, NC; Parminder Singh, 
      Mayo Clinic, Phoenix, AZ; Mohammed M. Milhem, University of Iowa Hospitals and 
      Clinics, Iowa City, IA; John Glaspy, University of California Los Angeles School 
      of Medicine; Omid Hamid, The Angeles Clinic and Research Institute, Los Angeles; 
      Lisa Chen, Jenny J. Kim, and Jennifer Gansert, Amgen, Thousand Oaks, CA; Merrick 
      Ross, MD Anderson Cancer Center, Houston, TX; Claus Garbe, University Hospital 
      Tuebingen, Tuebingen; Axel Hauschild, University of Kiel, Kiel, Germany; Theodore 
      F. Logan, Indiana University Simon Cancer Center, Indianapolis, IN; Celeste 
      Lebbe, Assistance Publique-Hopital De Paris Dermatology and CIC Hopital Saint 
      Louis University Paris Diderot Sorbonne, Institut National de la Sante et de la 
      Recherche Medicale U976, Paris, France; Robert H.I. Andtbacka, University of 
      Utah, Salt Lake City, UT; and Howard L. Kaufman, Rutgers Cancer Institute of New 
      Jersey, New Brunswick, NJ.
FAU - Hamid, Omid
AU  - Hamid O
AD  - Jason Chesney, J. Graham Brown Cancer Center, University of Louisville, 
      Louisville, KY; Igor Puzanov, Roswell Park Cancer Institute, Buffalo; Philip 
      Friedlander, Mt Sinai School of Medicine, New York, NY; Frances Collichio, The 
      University of North Carolina at Chapel Hill, Chapel Hill, NC; Parminder Singh, 
      Mayo Clinic, Phoenix, AZ; Mohammed M. Milhem, University of Iowa Hospitals and 
      Clinics, Iowa City, IA; John Glaspy, University of California Los Angeles School 
      of Medicine; Omid Hamid, The Angeles Clinic and Research Institute, Los Angeles; 
      Lisa Chen, Jenny J. Kim, and Jennifer Gansert, Amgen, Thousand Oaks, CA; Merrick 
      Ross, MD Anderson Cancer Center, Houston, TX; Claus Garbe, University Hospital 
      Tuebingen, Tuebingen; Axel Hauschild, University of Kiel, Kiel, Germany; Theodore 
      F. Logan, Indiana University Simon Cancer Center, Indianapolis, IN; Celeste 
      Lebbe, Assistance Publique-Hopital De Paris Dermatology and CIC Hopital Saint 
      Louis University Paris Diderot Sorbonne, Institut National de la Sante et de la 
      Recherche Medicale U976, Paris, France; Robert H.I. Andtbacka, University of 
      Utah, Salt Lake City, UT; and Howard L. Kaufman, Rutgers Cancer Institute of New 
      Jersey, New Brunswick, NJ.
FAU - Ross, Merrick
AU  - Ross M
AD  - Jason Chesney, J. Graham Brown Cancer Center, University of Louisville, 
      Louisville, KY; Igor Puzanov, Roswell Park Cancer Institute, Buffalo; Philip 
      Friedlander, Mt Sinai School of Medicine, New York, NY; Frances Collichio, The 
      University of North Carolina at Chapel Hill, Chapel Hill, NC; Parminder Singh, 
      Mayo Clinic, Phoenix, AZ; Mohammed M. Milhem, University of Iowa Hospitals and 
      Clinics, Iowa City, IA; John Glaspy, University of California Los Angeles School 
      of Medicine; Omid Hamid, The Angeles Clinic and Research Institute, Los Angeles; 
      Lisa Chen, Jenny J. Kim, and Jennifer Gansert, Amgen, Thousand Oaks, CA; Merrick 
      Ross, MD Anderson Cancer Center, Houston, TX; Claus Garbe, University Hospital 
      Tuebingen, Tuebingen; Axel Hauschild, University of Kiel, Kiel, Germany; Theodore 
      F. Logan, Indiana University Simon Cancer Center, Indianapolis, IN; Celeste 
      Lebbe, Assistance Publique-Hopital De Paris Dermatology and CIC Hopital Saint 
      Louis University Paris Diderot Sorbonne, Institut National de la Sante et de la 
      Recherche Medicale U976, Paris, France; Robert H.I. Andtbacka, University of 
      Utah, Salt Lake City, UT; and Howard L. Kaufman, Rutgers Cancer Institute of New 
      Jersey, New Brunswick, NJ.
FAU - Friedlander, Philip
AU  - Friedlander P
AD  - Jason Chesney, J. Graham Brown Cancer Center, University of Louisville, 
      Louisville, KY; Igor Puzanov, Roswell Park Cancer Institute, Buffalo; Philip 
      Friedlander, Mt Sinai School of Medicine, New York, NY; Frances Collichio, The 
      University of North Carolina at Chapel Hill, Chapel Hill, NC; Parminder Singh, 
      Mayo Clinic, Phoenix, AZ; Mohammed M. Milhem, University of Iowa Hospitals and 
      Clinics, Iowa City, IA; John Glaspy, University of California Los Angeles School 
      of Medicine; Omid Hamid, The Angeles Clinic and Research Institute, Los Angeles; 
      Lisa Chen, Jenny J. Kim, and Jennifer Gansert, Amgen, Thousand Oaks, CA; Merrick 
      Ross, MD Anderson Cancer Center, Houston, TX; Claus Garbe, University Hospital 
      Tuebingen, Tuebingen; Axel Hauschild, University of Kiel, Kiel, Germany; Theodore 
      F. Logan, Indiana University Simon Cancer Center, Indianapolis, IN; Celeste 
      Lebbe, Assistance Publique-Hopital De Paris Dermatology and CIC Hopital Saint 
      Louis University Paris Diderot Sorbonne, Institut National de la Sante et de la 
      Recherche Medicale U976, Paris, France; Robert H.I. Andtbacka, University of 
      Utah, Salt Lake City, UT; and Howard L. Kaufman, Rutgers Cancer Institute of New 
      Jersey, New Brunswick, NJ.
FAU - Garbe, Claus
AU  - Garbe C
AD  - Jason Chesney, J. Graham Brown Cancer Center, University of Louisville, 
      Louisville, KY; Igor Puzanov, Roswell Park Cancer Institute, Buffalo; Philip 
      Friedlander, Mt Sinai School of Medicine, New York, NY; Frances Collichio, The 
      University of North Carolina at Chapel Hill, Chapel Hill, NC; Parminder Singh, 
      Mayo Clinic, Phoenix, AZ; Mohammed M. Milhem, University of Iowa Hospitals and 
      Clinics, Iowa City, IA; John Glaspy, University of California Los Angeles School 
      of Medicine; Omid Hamid, The Angeles Clinic and Research Institute, Los Angeles; 
      Lisa Chen, Jenny J. Kim, and Jennifer Gansert, Amgen, Thousand Oaks, CA; Merrick 
      Ross, MD Anderson Cancer Center, Houston, TX; Claus Garbe, University Hospital 
      Tuebingen, Tuebingen; Axel Hauschild, University of Kiel, Kiel, Germany; Theodore 
      F. Logan, Indiana University Simon Cancer Center, Indianapolis, IN; Celeste 
      Lebbe, Assistance Publique-Hopital De Paris Dermatology and CIC Hopital Saint 
      Louis University Paris Diderot Sorbonne, Institut National de la Sante et de la 
      Recherche Medicale U976, Paris, France; Robert H.I. Andtbacka, University of 
      Utah, Salt Lake City, UT; and Howard L. Kaufman, Rutgers Cancer Institute of New 
      Jersey, New Brunswick, NJ.
FAU - Logan, Theodore F
AU  - Logan TF
AD  - Jason Chesney, J. Graham Brown Cancer Center, University of Louisville, 
      Louisville, KY; Igor Puzanov, Roswell Park Cancer Institute, Buffalo; Philip 
      Friedlander, Mt Sinai School of Medicine, New York, NY; Frances Collichio, The 
      University of North Carolina at Chapel Hill, Chapel Hill, NC; Parminder Singh, 
      Mayo Clinic, Phoenix, AZ; Mohammed M. Milhem, University of Iowa Hospitals and 
      Clinics, Iowa City, IA; John Glaspy, University of California Los Angeles School 
      of Medicine; Omid Hamid, The Angeles Clinic and Research Institute, Los Angeles; 
      Lisa Chen, Jenny J. Kim, and Jennifer Gansert, Amgen, Thousand Oaks, CA; Merrick 
      Ross, MD Anderson Cancer Center, Houston, TX; Claus Garbe, University Hospital 
      Tuebingen, Tuebingen; Axel Hauschild, University of Kiel, Kiel, Germany; Theodore 
      F. Logan, Indiana University Simon Cancer Center, Indianapolis, IN; Celeste 
      Lebbe, Assistance Publique-Hopital De Paris Dermatology and CIC Hopital Saint 
      Louis University Paris Diderot Sorbonne, Institut National de la Sante et de la 
      Recherche Medicale U976, Paris, France; Robert H.I. Andtbacka, University of 
      Utah, Salt Lake City, UT; and Howard L. Kaufman, Rutgers Cancer Institute of New 
      Jersey, New Brunswick, NJ.
FAU - Hauschild, Axel
AU  - Hauschild A
AD  - Jason Chesney, J. Graham Brown Cancer Center, University of Louisville, 
      Louisville, KY; Igor Puzanov, Roswell Park Cancer Institute, Buffalo; Philip 
      Friedlander, Mt Sinai School of Medicine, New York, NY; Frances Collichio, The 
      University of North Carolina at Chapel Hill, Chapel Hill, NC; Parminder Singh, 
      Mayo Clinic, Phoenix, AZ; Mohammed M. Milhem, University of Iowa Hospitals and 
      Clinics, Iowa City, IA; John Glaspy, University of California Los Angeles School 
      of Medicine; Omid Hamid, The Angeles Clinic and Research Institute, Los Angeles; 
      Lisa Chen, Jenny J. Kim, and Jennifer Gansert, Amgen, Thousand Oaks, CA; Merrick 
      Ross, MD Anderson Cancer Center, Houston, TX; Claus Garbe, University Hospital 
      Tuebingen, Tuebingen; Axel Hauschild, University of Kiel, Kiel, Germany; Theodore 
      F. Logan, Indiana University Simon Cancer Center, Indianapolis, IN; Celeste 
      Lebbe, Assistance Publique-Hopital De Paris Dermatology and CIC Hopital Saint 
      Louis University Paris Diderot Sorbonne, Institut National de la Sante et de la 
      Recherche Medicale U976, Paris, France; Robert H.I. Andtbacka, University of 
      Utah, Salt Lake City, UT; and Howard L. Kaufman, Rutgers Cancer Institute of New 
      Jersey, New Brunswick, NJ.
FAU - Lebbe, Celeste
AU  - Lebbe C
AD  - Jason Chesney, J. Graham Brown Cancer Center, University of Louisville, 
      Louisville, KY; Igor Puzanov, Roswell Park Cancer Institute, Buffalo; Philip 
      Friedlander, Mt Sinai School of Medicine, New York, NY; Frances Collichio, The 
      University of North Carolina at Chapel Hill, Chapel Hill, NC; Parminder Singh, 
      Mayo Clinic, Phoenix, AZ; Mohammed M. Milhem, University of Iowa Hospitals and 
      Clinics, Iowa City, IA; John Glaspy, University of California Los Angeles School 
      of Medicine; Omid Hamid, The Angeles Clinic and Research Institute, Los Angeles; 
      Lisa Chen, Jenny J. Kim, and Jennifer Gansert, Amgen, Thousand Oaks, CA; Merrick 
      Ross, MD Anderson Cancer Center, Houston, TX; Claus Garbe, University Hospital 
      Tuebingen, Tuebingen; Axel Hauschild, University of Kiel, Kiel, Germany; Theodore 
      F. Logan, Indiana University Simon Cancer Center, Indianapolis, IN; Celeste 
      Lebbe, Assistance Publique-Hopital De Paris Dermatology and CIC Hopital Saint 
      Louis University Paris Diderot Sorbonne, Institut National de la Sante et de la 
      Recherche Medicale U976, Paris, France; Robert H.I. Andtbacka, University of 
      Utah, Salt Lake City, UT; and Howard L. Kaufman, Rutgers Cancer Institute of New 
      Jersey, New Brunswick, NJ.
FAU - Chen, Lisa
AU  - Chen L
AD  - Jason Chesney, J. Graham Brown Cancer Center, University of Louisville, 
      Louisville, KY; Igor Puzanov, Roswell Park Cancer Institute, Buffalo; Philip 
      Friedlander, Mt Sinai School of Medicine, New York, NY; Frances Collichio, The 
      University of North Carolina at Chapel Hill, Chapel Hill, NC; Parminder Singh, 
      Mayo Clinic, Phoenix, AZ; Mohammed M. Milhem, University of Iowa Hospitals and 
      Clinics, Iowa City, IA; John Glaspy, University of California Los Angeles School 
      of Medicine; Omid Hamid, The Angeles Clinic and Research Institute, Los Angeles; 
      Lisa Chen, Jenny J. Kim, and Jennifer Gansert, Amgen, Thousand Oaks, CA; Merrick 
      Ross, MD Anderson Cancer Center, Houston, TX; Claus Garbe, University Hospital 
      Tuebingen, Tuebingen; Axel Hauschild, University of Kiel, Kiel, Germany; Theodore 
      F. Logan, Indiana University Simon Cancer Center, Indianapolis, IN; Celeste 
      Lebbe, Assistance Publique-Hopital De Paris Dermatology and CIC Hopital Saint 
      Louis University Paris Diderot Sorbonne, Institut National de la Sante et de la 
      Recherche Medicale U976, Paris, France; Robert H.I. Andtbacka, University of 
      Utah, Salt Lake City, UT; and Howard L. Kaufman, Rutgers Cancer Institute of New 
      Jersey, New Brunswick, NJ.
FAU - Kim, Jenny J
AU  - Kim JJ
AD  - Jason Chesney, J. Graham Brown Cancer Center, University of Louisville, 
      Louisville, KY; Igor Puzanov, Roswell Park Cancer Institute, Buffalo; Philip 
      Friedlander, Mt Sinai School of Medicine, New York, NY; Frances Collichio, The 
      University of North Carolina at Chapel Hill, Chapel Hill, NC; Parminder Singh, 
      Mayo Clinic, Phoenix, AZ; Mohammed M. Milhem, University of Iowa Hospitals and 
      Clinics, Iowa City, IA; John Glaspy, University of California Los Angeles School 
      of Medicine; Omid Hamid, The Angeles Clinic and Research Institute, Los Angeles; 
      Lisa Chen, Jenny J. Kim, and Jennifer Gansert, Amgen, Thousand Oaks, CA; Merrick 
      Ross, MD Anderson Cancer Center, Houston, TX; Claus Garbe, University Hospital 
      Tuebingen, Tuebingen; Axel Hauschild, University of Kiel, Kiel, Germany; Theodore 
      F. Logan, Indiana University Simon Cancer Center, Indianapolis, IN; Celeste 
      Lebbe, Assistance Publique-Hopital De Paris Dermatology and CIC Hopital Saint 
      Louis University Paris Diderot Sorbonne, Institut National de la Sante et de la 
      Recherche Medicale U976, Paris, France; Robert H.I. Andtbacka, University of 
      Utah, Salt Lake City, UT; and Howard L. Kaufman, Rutgers Cancer Institute of New 
      Jersey, New Brunswick, NJ.
FAU - Gansert, Jennifer
AU  - Gansert J
AD  - Jason Chesney, J. Graham Brown Cancer Center, University of Louisville, 
      Louisville, KY; Igor Puzanov, Roswell Park Cancer Institute, Buffalo; Philip 
      Friedlander, Mt Sinai School of Medicine, New York, NY; Frances Collichio, The 
      University of North Carolina at Chapel Hill, Chapel Hill, NC; Parminder Singh, 
      Mayo Clinic, Phoenix, AZ; Mohammed M. Milhem, University of Iowa Hospitals and 
      Clinics, Iowa City, IA; John Glaspy, University of California Los Angeles School 
      of Medicine; Omid Hamid, The Angeles Clinic and Research Institute, Los Angeles; 
      Lisa Chen, Jenny J. Kim, and Jennifer Gansert, Amgen, Thousand Oaks, CA; Merrick 
      Ross, MD Anderson Cancer Center, Houston, TX; Claus Garbe, University Hospital 
      Tuebingen, Tuebingen; Axel Hauschild, University of Kiel, Kiel, Germany; Theodore 
      F. Logan, Indiana University Simon Cancer Center, Indianapolis, IN; Celeste 
      Lebbe, Assistance Publique-Hopital De Paris Dermatology and CIC Hopital Saint 
      Louis University Paris Diderot Sorbonne, Institut National de la Sante et de la 
      Recherche Medicale U976, Paris, France; Robert H.I. Andtbacka, University of 
      Utah, Salt Lake City, UT; and Howard L. Kaufman, Rutgers Cancer Institute of New 
      Jersey, New Brunswick, NJ.
FAU - Andtbacka, Robert H I
AU  - Andtbacka RHI
AD  - Jason Chesney, J. Graham Brown Cancer Center, University of Louisville, 
      Louisville, KY; Igor Puzanov, Roswell Park Cancer Institute, Buffalo; Philip 
      Friedlander, Mt Sinai School of Medicine, New York, NY; Frances Collichio, The 
      University of North Carolina at Chapel Hill, Chapel Hill, NC; Parminder Singh, 
      Mayo Clinic, Phoenix, AZ; Mohammed M. Milhem, University of Iowa Hospitals and 
      Clinics, Iowa City, IA; John Glaspy, University of California Los Angeles School 
      of Medicine; Omid Hamid, The Angeles Clinic and Research Institute, Los Angeles; 
      Lisa Chen, Jenny J. Kim, and Jennifer Gansert, Amgen, Thousand Oaks, CA; Merrick 
      Ross, MD Anderson Cancer Center, Houston, TX; Claus Garbe, University Hospital 
      Tuebingen, Tuebingen; Axel Hauschild, University of Kiel, Kiel, Germany; Theodore 
      F. Logan, Indiana University Simon Cancer Center, Indianapolis, IN; Celeste 
      Lebbe, Assistance Publique-Hopital De Paris Dermatology and CIC Hopital Saint 
      Louis University Paris Diderot Sorbonne, Institut National de la Sante et de la 
      Recherche Medicale U976, Paris, France; Robert H.I. Andtbacka, University of 
      Utah, Salt Lake City, UT; and Howard L. Kaufman, Rutgers Cancer Institute of New 
      Jersey, New Brunswick, NJ.
FAU - Kaufman, Howard L
AU  - Kaufman HL
AD  - Jason Chesney, J. Graham Brown Cancer Center, University of Louisville, 
      Louisville, KY; Igor Puzanov, Roswell Park Cancer Institute, Buffalo; Philip 
      Friedlander, Mt Sinai School of Medicine, New York, NY; Frances Collichio, The 
      University of North Carolina at Chapel Hill, Chapel Hill, NC; Parminder Singh, 
      Mayo Clinic, Phoenix, AZ; Mohammed M. Milhem, University of Iowa Hospitals and 
      Clinics, Iowa City, IA; John Glaspy, University of California Los Angeles School 
      of Medicine; Omid Hamid, The Angeles Clinic and Research Institute, Los Angeles; 
      Lisa Chen, Jenny J. Kim, and Jennifer Gansert, Amgen, Thousand Oaks, CA; Merrick 
      Ross, MD Anderson Cancer Center, Houston, TX; Claus Garbe, University Hospital 
      Tuebingen, Tuebingen; Axel Hauschild, University of Kiel, Kiel, Germany; Theodore 
      F. Logan, Indiana University Simon Cancer Center, Indianapolis, IN; Celeste 
      Lebbe, Assistance Publique-Hopital De Paris Dermatology and CIC Hopital Saint 
      Louis University Paris Diderot Sorbonne, Institut National de la Sante et de la 
      Recherche Medicale U976, Paris, France; Robert H.I. Andtbacka, University of 
      Utah, Salt Lake City, UT; and Howard L. Kaufman, Rutgers Cancer Institute of New 
      Jersey, New Brunswick, NJ.
LA  - eng
SI  - ClinicalTrials.gov/NCT01740297
GR  - P30 CA086862/CA/NCI NIH HHS/United States
PT  - Clinical Trial, Phase II
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20171005
PL  - United States
TA  - J Clin Oncol
JT  - Journal of clinical oncology : official journal of the American Society of 
      Clinical Oncology
JID - 8309333
RN  - 0 (Biological Products)
RN  - 0 (Ipilimumab)
RN  - 0 (talimogene laherparepvec)
RN  - EC 2.7.11.1 (BRAF protein, human)
RN  - EC 2.7.11.1 (Proto-Oncogene Proteins B-raf)
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use
MH  - Biological Products/administration & dosage/adverse effects
MH  - Female
MH  - Herpesvirus 1, Human
MH  - Humans
MH  - Ipilimumab/administration & dosage/adverse effects/*therapeutic use
MH  - Male
MH  - Melanoma/*drug therapy/enzymology/genetics/pathology
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Progression-Free Survival
MH  - Proto-Oncogene Proteins B-raf/genetics
MH  - Skin Neoplasms/*drug therapy/enzymology/genetics/pathology
MH  - Young Adult
PMC - PMC6075852
EDAT- 2017/10/06 06:00
MHDA- 2019/08/06 06:00
PMCR- 2018/08/10
CRDT- 2017/10/06 06:00
PHST- 2017/10/06 06:00 [pubmed]
PHST- 2019/08/06 06:00 [medline]
PHST- 2017/10/06 06:00 [entrez]
PHST- 2018/08/10 00:00 [pmc-release]
AID - 737379 [pii]
AID - 10.1200/JCO.2017.73.7379 [doi]
PST - ppublish
SO  - J Clin Oncol. 2018 Jun 10;36(17):1658-1667. doi: 10.1200/JCO.2017.73.7379. Epub 
      2017 Oct 5.